| JWA level | XRCC1 level | BRCA1 level | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Low | High | P value | Low | High | P value | Low | High | P value | mOS (95%CI) | P value |
Age, y | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
≤62 | 39 | 36 |  | 40 | 35 |  | 37 | 38 |  | 13.0(11.3-14.8) |  |
>62 | 34 | 36 | 0.741 | 33 | 37 | 0.456 | 37 | 33 | 0.671 | 13.0(10.0-16.0) | 0.805 |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Males | 53 | 39 | Â | 52 | 40 | Â | 47 | 45 | Â | 12.0(10.1-13.9) | Â |
Females | 20 | 33 | 0.025 | 21 | 32 | 0.053 | 27 | 26 | 0.987 | 16.0(13.4-18.6) | 0.007 |
ECOG, PS | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
0-1 | 66 | 67 | Â | 68 | 65 | Â | 67 | 66 | Â | 14.0(12.3-15.4) | Â |
2 | 6 | 6 | 0.98 | 5 | 7 | 0.53 | 7 | 5 | 0.597 | 6.0(4.9-7.8) | <0.001 |
TNM stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
II | 12 | 16 | Â | 14 | 14 | Â | 18 | 10 | Â | 14.0(11.9-16.1) | Â |
III | 25 | 22 | Â | 25 | 22 | Â | 22 | 25 | Â | 10.0(8.3-11.7) | 0.096 |
IV | 36 | 34 | 0.666 | 34 | 36 | 0.886 | 34 | 36 | 0.290 | 14.0(11.4-14.6) | 0.656 |
G stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
G1 | 5 | 15 | Â | 7 | 13 | Â | 9 | 11 | Â | 18.5(15.8-21.2) | Â |
G2 | 48 | 42 | Â | 47 | 43 | Â | 50 | 40 | Â | 13.0(11.4-14.7) | 0.061 |
G3 | 20 | 15 | 0.047 | 19 | 16 | 0.328 | 15 | 20 | 0.375 | 9.0(6.7-11.3) | 0.005 |